3 Nevertheless, we would like to make some points clear.
To sustain their argument, the authors reference an open, uncontrolled study, including a total of 13 patients (16-week duration) who underwent dietary intervention. 4 The results have to be cautiously analysed-the patients had an extraordinarily high rate of flares in the 4 months before entering the study (2.1 per month); despite the mean serum urate at the end of the study (470 μmol/l [7.8 mg/dl]), the rate of flares dramatically sunk to 0.6 per month (a 71% decrease), a reduction that even surpasses canakinumab in clinical trials.
5 Finally, the short-term weight-loss observed is not necessarily associated with maintenance of such loss in the longterm, as shown by the cited paper. 6 In the Multiple Risk Factor Intervention Trial, at 7-year follow-up, only 14.39% of patients had lost ≥5 kg, and 73% had a BMI of >25 at baseline. 6 In a large, follow-up of a cohort of patients with gout, only 13% of patients withdrew from urate-lowering medications in the long-term and maintained normal serum urate levels; weight loss, but also other environmental factors, was associated with this outcome. 7 The authors remark that the benefit of proper control of comorbid conditions might be of more benefit than the mere control of urate, referencing ACR recommendations. 8 We assume they regard comor bid conditions as cardiovascular risk factors. Quoting the 2012 ACR recommendations, the panel "…recognized that
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Gout treatment-more tablets might be needed Fernando Perez-Ruiz and Ana Maria Herrero-Beites diet and lifestyle measures alone provide therapeutically insufficient serum uratelowering effects or gout attack prophylaxis for a large fraction of indivi duals with gout."
8 In addition, we completely agree that proper control of comorbid conditions, such as diabetes, hypertension and hyperlipidaemia, should be addressed; in a considerable number of cases they will not be properly controlled with lifestyle modifications alone, and therefore a tablet for hyperuricaemia will not be enough-more tablets might be needed.
Alvarez-Lario and Alonso-Valdivieso support their assertions by referencing two educational interventions, including lifestyle education.
9,10 Specific results of lifestyle intervention were not reported in either of these papers and 80-100% of patients were prescribed increasing doses of urate-lowering medications, and switched to other drugs if needed to achieve proper urate control. In these studies, education centred mostly on knowledge of the disease, therapeutic targets, outcomes ("curing gout"), and correct implementation of prescriptions. In one particular gout clinic, similar figures were reported, with almost 80% of patients achieving proper control of urate at a 4-year follow-up.
11 It is of great interest that such interventions are far better than results from audits of the management of gout. 12 We agree that environmental modification interventions in gout might be critical, and we consider the education of doctors (a powerful environmental factor), in addition to that of patients, as especially important.
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